A vitamin D analog inhibits Th2 cytokine- and TGFβ -induced periostin production in fibroblasts: a potential role for vitamin D in skin sclerosis

References

• Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol 2013; 31:432-7; PMID:23806160; http://dx.doi.org/10.1016/j.clindermatol.2013.01.010
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006; 140:345-56; PMID:16804319; http://dx.doi.org/10.1159/000094242
   PubMed Web of Science ®Google Scholar
• Arnson Y, Amital H, Agmon-Levin N, Alon D, Sanchez-Castanon M, Lopez-Hoyos M, Matucci-Cerinic M, Szucs G, Shapira Y, Szekanecz Z, et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011; 10:490-4; PMID:21320645; http://dx.doi.org/10.1016/j.autrev.2011.02.002
   PubMed Web of Science ®Google Scholar
• Gambichler T, Chrobok I, Hoxtermann S, Kreuter A. Significantly decreased serum 25-hydroxyvitamin d levels in a large german systemic sclerosis cohort. J Rheumatol 2011; 38:2492-3; author reply 4; PMID:22045936; http://dx.doi.org/10.3899/jrheum.110695
   PubMed Web of Science ®Google Scholar
• Vacca A, Cormier C, Mathieu A, Kahan A, Allanore Y. Vitamin D levels and potential impact in systemic sclerosis. Clin Exp Rheumatol 2011; 29:1024-31; PMID:22011638
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Dalla Gassa A, Ruzzenente O, Volpe A, Ravagnani V, Tinazzi I, Barausse G, Bambara LM, Biasi D. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010; 29:1419-25; PMID:20454816; http://dx.doi.org/10.1007/s10067-010-1478-3
   PubMed Web of Science ®Google Scholar
• Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012; 12:127-36; PMID:22776787; http://dx.doi.org/10.1016/j.autrev.2012.07.007
   PubMed Web of Science ®Google Scholar
• Hulshof MM, Bouwes Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC, Dijkmans BA. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43:1017-23; PMID:11100017; http://dx.doi.org/10.1067/mjd.2000.108369
   PubMed Web of Science ®Google Scholar
• Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi DV, Pesic NP, Laskoski DS. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999; 455:299-304; PMID:10599359; http://dx.doi.org/10.1007/978-1-4615-4857-7_44
   PubMed Web of Science ®Google Scholar
• Kieffer MA. Topical vitamin D analogs. Dermatol Nurs 2004; 16:89-90, 3, 100; PMID:15022510
   PubMedGoogle Scholar
• Tay YK. Topical calcipotriol ointment in the treatment of morphea. J Dermatolog Treat 2003; 14:219-21; PMID:14660267; http://dx.doi.org/10.1080/09546630310015449
   PubMedGoogle Scholar
• Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998; 39:211-5; PMID:9704831; http://dx.doi.org/10.1016/S0190-9622(98)70077-5
   PubMed Web of Science ®Google Scholar
• Koeger AC, Rozenberg S, Fautrel B. Effectiveness of topical calcitriol for localized scleroderma. J Rheumatol 1999; 26:239-40; PMID:9918276
   PubMed Web of Science ®Google Scholar
• Bottomley WW, Jutley J, Wood EJ, Goodfield MD. The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. Acta Derm Venereol 1995; 75:364-6; PMID:8615053
   PubMed Web of Science ®Google Scholar
• Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, Matsui S, Kudo A, Naka T, Murota H, et al. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. PloS one 2012; 7:e41994; PMID:22911870; http://dx.doi.org/10.1371/journal.pone.0041994
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, Aihara M, Takahashi K. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. The British journal of dermatology 2013; 168:717-25; PMID:23110679; http://dx.doi.org/10.1111/bjd.12117
   PubMed Web of Science ®Google Scholar
• Yang L, Murota H, Serada S, Fujimoto M, Kudo A, Naka T, Katayama I. Histamine contributes to tissue remodeling via periostin expression. J Invest Dermatol 2014; 134(8):2105-13; PMID:24577408; http://dx.doi.org/10.1038/jid.2014.120
   PubMed Web of Science ®Google Scholar
• Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 2012; 122:2590-600; PMID:22684102; http://dx.doi.org/10.1172/JCI58978
   PubMed Web of Science ®Google Scholar
• Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118:98-104; PMID:16815144; http://dx.doi.org/10.1016/j.jaci.2006.02.046
   PubMed Web of Science ®Google Scholar
• Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141:274-8; PMID:10468799; http://dx.doi.org/10.1046/j.1365-2133.1999.02975.x
   PubMed Web of Science ®Google Scholar
• Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-alpha processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010; 19:38-43; PMID:19758314; http://dx.doi.org/10.1111/j.1600-0625.2009.00973.x
   PubMed Web of Science ®Google Scholar
• Slominski A, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya KG, Wang J, Li W, Jiao Y, Gu W, Brown M, et al. 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab 2013; 98:E298-303; PMID:23295467; http://dx.doi.org/10.1210/jc.2012-3074
   PubMedGoogle Scholar
• Kurzinski K, Torok KS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011; 55:157-64; PMID:21536453; http://dx.doi.org/10.1016/j.cyto.2011.04.001
   PubMed Web of Science ®Google Scholar
• O'Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 2012; 51:1540-9; PMID:22577083; http://dx.doi.org/10.1093/rheumatology/kes090
   PubMed Web of Science ®Google Scholar
• Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180:165-76; PMID:22062222; http://dx.doi.org/10.1016/j.ajpath.2011.09.013
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, Arimitsu J, Narazaki M, Hagihara K, Ogata A, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010; 49:2408-12; PMID:20819796; http://dx.doi.org/10.1093/rheumatology/keq275
   PubMed Web of Science ®Google Scholar
• Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, Zugel U, Steinmeyer A, Pollak A, Roth E, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36:361-70; PMID:16402404; http://dx.doi.org/10.1002/eji.200425995
   PubMed Web of Science ®Google Scholar
• Khoo AL, Chai LY, Koenen HJ, Sweep FC, Joosten I, Netea MG, van der Ven AJ. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011; 164:72-9; PMID:21323660; http://dx.doi.org/10.1111/j.1365-2249.2010.04315.x
   PubMed Web of Science ®Google Scholar
• Koizumi H, Kaplan A, Shimizu T, Ohkawara A. 1,25-Dihydroxyvitamin D3 and a new analogue, 22-oxacalcitriol, modulate proliferation and interleukin-8 secretion of normal human keratinocytes. J Dermatol Sci 1997; 15:207-13; PMID:9302649; http://dx.doi.org/10.1016/S0923-1811(97)00609-9
   PubMed Web of Science ®Google Scholar
• Komine M, Watabe Y, Shimaoka S, Sato F, Kake K, Nishina H, Ohtsuki M, Nakagawa H, Tamaki K. The action of a novel vitamin D3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes. Arch Dermatol Res 1999; 291:500-6; PMID:10541880; http://dx.doi.org/10.1007/s004030050444
   PubMed Web of Science ®Google Scholar